Literature DB >> 34509526

Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.

Qinjunjie Chen1, Haibo Wang1, Zheng Li1, Fengwei Li2, Leilei Liang3, Yiran Zou1, Hao Shen4, Jun Li1, Yong Xia1, Zhangjun Cheng5, Tian Yang4, Kui Wang6, Feng Shen7.   

Abstract

BACKGROUND & AIMS: Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer with high aggressiveness and extremely poor prognosis. The role of circular RNAs (circRNAs) in ICC carcinogenesis and progression remains to be determined.
METHODS: CircRNA microarray was performed to screen significantly upregulated circRNAs in paired ICC and non-tumor tissues. Colony formation, transwell, and xenograft models were used to examine the role of circRNAs in ICC proliferation and metastasis. RNA pulldown, mass spectrometry, chromatin immunoprecipitation, RNA-binding protein immunoprecipitation, chromatin isolation by RNA purification, electrophoretic mobility shift assay, and luciferase reporter assays were used to explore the molecular sponge role of the circRNA (via miRNA binding), and the interaction between circRNA and RNA-binding proteins.
RESULTS: Hsa_circ_0050898, which originated from exon 1 to exon 20 of the ACTN4 gene (named circACTN4), was significantly upregulated in ICC. High circACTN4 expression was associated with enhanced tumor proliferation and metastasis in vitro and in vivo, as well as a worse prognosis following ICC resection. In addition, circACTN4 upregulated Yes-associated protein 1 (YAP1) expression by sponging miR-424-5p. More importantly, circACTN4 also recruited Y-box binding protein 1 (YBX1) to stimulate Frizzled-7 (FZD7) transcription. Furthermore, circACTN4 overexpression in ICC cells enhanced the interaction between YAP1 and β-catenin, which are the core components of the Hippo and Wnt signaling pathways, respectively.
CONCLUSIONS: CircACTN4 was upregulated in ICC and promoted ICC proliferation and metastasis by acting as a molecular sponge of miR-424-5p, as well as by interacting with YBX1 to transcriptionally activate FZD7. These results suggest that circACTN4 is a potential prognostic marker and therapeutic target for ICC. LAY
SUMMARY: Intrahepatic cholangiocarcinoma is a primary liver cancer associated with aggressiveness and extremely poor prognosis. It is essential for therapeutic development that we uncover relevant pathogenic pathways. Herein, we showed that a circular RNA (circACTN4) was highly expressed in intrahepatic cholangiocarcinoma and was positively associated with tumor growth and metastasis through key developmental signaling pathways. Thus, circACTN4 could be a prognostic biomarker and therapeutic target for intrahepatic cholangiocarcinoma.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FZD7; Hippo; Intrahepatic cholangiocarcinoma; Wnt; YAP1; circACTN4

Mesh:

Substances:

Year:  2021        PMID: 34509526     DOI: 10.1016/j.jhep.2021.08.027

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  LncRNA RAD51-AS1 Regulates Human Bone Marrow Mesenchymal Stem Cells via Interaction with YBX1 to Ameliorate Osteoporosis.

Authors:  Beichen Li; Jing Wang; Fangrong Xu; Qinjue Wang; Quan Liu; Guantong Wang; Dengshun Miao; Qiang Sun
Journal:  Stem Cell Rev Rep       Date:  2022-06-21       Impact factor: 5.739

2.  CircNRIP1 acts as a sponge of miR-1200 to suppress osteosarcoma progression via upregulation of MIA2.

Authors:  Ruoxuan Hei; Jinnan Chen; Xiaojing Zhang; Huiqin Bian; Chen Chen; Xuan Wu; Tiaotiao Han; Yiming Zhang; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

3.  circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA.

Authors:  Lifeng Ding; Ruyue Wang; Qiming Zheng; Danyang Shen; Huan Wang; Zeyi Lu; Wenqin Luo; Haiyun Xie; Liangliang Ren; Minxiao Jiang; Chenhao Yu; Zhenwei Zhou; Yudong Lin; Haohua Lu; Dingwei Xue; Wenjing Su; Liqun Xia; Jochen Neuhaus; Sheng Cheng; Gonghui Li
Journal:  J Exp Clin Cancer Res       Date:  2022-06-02

4.  circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop.

Authors:  Xiaomin Li; Jianjun Wang; Weihao Lin; Qinzi Yuan; Yanxia Lu; Haowei Wang; Yujia Chen; Lixia Chen; Peiling Dai; Huaicheng Long; Xuenong Li
Journal:  Mol Cancer       Date:  2022-06-23       Impact factor: 41.444

Review 5.  Specific expression and functions of circular RNAs.

Authors:  Sema Misir; Nan Wu; Burton B Yang
Journal:  Cell Death Differ       Date:  2022-02-15       Impact factor: 12.067

Review 6.  Emerging roles of circular RNAs in liver cancer.

Authors:  Corentin Louis; Delphine Leclerc; Cédric Coulouarn
Journal:  JHEP Rep       Date:  2021-11-27

Review 7.  YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy.

Authors:  Qiyan Yin; Min Zheng; Qianmei Luo; Dewei Jiang; Huifeng Zhang; Ceshi Chen
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

8.  WWP1 upregulation predicts poor prognosis and promotes tumor progression by regulating ubiquitination of NDFIP1 in intrahepatic cholangiocarcinoma.

Authors:  Yongjian Li; Qian Cheng; Jie Gao; Zhuomiaoyu Chen; Jingheng Guo; Zuyin Li; Lingyu Tian; Chao Zhang; Yuzi Li; Jiaxi Zheng; Zhao Li; Jiye Zhu
Journal:  Cell Death Discov       Date:  2022-03-09

Review 9.  Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors.

Authors:  Qiyang Shen; Xingyu Liu; Wei Li; Xu Zhao; Tao Li; Kai Zhou; Jianfeng Zhou
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

10.  Identification and Characterization of the Roles of circCASP9 in Gastric Cancer Based on a circRNA-miRNA-mRNA Regulatory Network.

Authors:  Chuan Qin; Han Zhang; Xiong Guo; Anqi Cheng; Huawen Liu; Ziwei Wang
Journal:  Oxid Med Cell Longev       Date:  2022-03-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.